Pre-POINT: Study for non-diabetic children with type 1 diabetes in the family
Pre-POINT is an international study to investigate insulin vaccination for type 1 diabetes prevention. Children take the insulin by mouth as a powder on a daily basis. Insulin given that way does not lower blood glucose, but is supposed to influence the immune system like a vaccination and to prevent the development of islet autoimmunity and type 1 diabetes.
The Pre-POINT study investigates an optimal insulin dosage for the vaccination in children with a very high risk for diabetes. Children taking part in Pre-POINT can also participate in the subsequent POINT study, if they wish to, where the effectiveness of the vaccination is being investigated.
In order to find children with a very high risk for diabetes, a diabetes risk screening is conducted. Children from all over Germany between 18 months and seven years of age and who have a sibling or two first grade relatives (father, mother, siblings) with type 1 diabetes can participate in the risk screening free of charge.
This study is supported by the Federal Ministry of Education and Research (BMBF) and the Juvenile Diabetes Research Foundation (JDRF).
For further information, please visit www.diabetes-point.org.
Contact person: Dr. Peter Achenbach, M.D., or Miriam Krasman, M.D.
Phone: +49- (0)89 / 3068 – 5573
Email: prevent.diabetes@lrz.uni-muenchen.de